CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease
Jennifer L Green, Dallin Dressman, Mamun Rashid, Ryan Hobson, Wassim Elyaman, Elizabeth M Bradshaw · 2025
Read CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease by Jennifer L Green, Dallin Dressman, Mamun Rashid, Ryan Hobson, Wassim Elyaman, Elizabeth M Bradshaw (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712427.txt.
Description
Jennifer Green and five co-authors tested a peptide that blocks a brake on the brain's immune cells, in a 2025 paper. Genes point to microglia, the brain's resident defenders, as drivers of Alzheimer's disease. One of their surface proteins, CD33, normally damps immune action. The team reasoned that blocking it might free microglia to clear amyloid plaques and calm harmful inflammation.
Their peptide, IMAD-001, competes with CD33's natural binding. In human cells grown in dishes, treated immune cells swallowed more amyloid. In mice bred to develop plaques, weekly injections cleared amyloid from the brain. Single-cell reading of brain immune cells showed shifts in cell types and states, including lower levels of a suppressive molecule. The authors present the peptide as a candidate worth developing toward therapy.
Catalog record
| CREATOR | Jennifer L Green, Dallin Dressman, Mamun Rashid, Ryan Hobson, Wassim Elyaman, Elizabeth M Bradshaw |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |